Perifosine in Treating Patients With Advanced Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT00053924|
Recruitment Status : Completed
First Posted : February 6, 2003
Last Update Posted : July 23, 2015
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced or metastatic pancreatic cancer.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Drug: perifosine||Phase 2|
- Determine the efficacy of perifosine, in terms of 6-month survival, in patients with advanced adenocarcinoma of the pancreas.
- Determine the safety and tolerability of this drug in these patients.
- Determine median survival time and the 1-year survival rate of patients treated with this drug.
- Determine the objective response rate (partial and complete), response duration, and time to progression in patients treated with this drug.
- Determine the toxicity of this drug in these patients.
OUTLINE: Patients receive oral perifosine daily for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 17-37 patients will be accrued for this study within 15 months.
|Study Type :||Interventional (Clinical Trial)|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Study Of Perifosine As Second Line Therapy For Advanced Pancreatic Carcinoma|
|Study Start Date :||May 2003|
|Actual Primary Completion Date :||May 2006|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00053924
|Margaret and Charles Juravinski Cancer Centre|
|Hamilton, Ontario, Canada, L8V 5C2|
|Cancer Care Ontario-London Regional Cancer Centre|
|London, Ontario, Canada, N6A 4L6|
|Princess Margaret Hospital|
|Toronto, Ontario, Canada, M5G 2M9|
|Study Chair:||Malcolm J. Moore, MD||Princess Margaret Hospital, Canada|